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The role of Tat in the human immunodeficiency virus life cycle
indicates a primary effect on transcriptional elongation
(viral transactivator/transcriptional elongation/elongation factor)
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*Whitehead Institute for Biomedical Research, Nine Cambridge Center, Cambridge, MA 02142; and tThe Rockefeller University, 1230 York Avenue, New
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ABSTRACT The mechanism of Tat transactivation was
studied by treating cell lines containing Tat-defective viruses
with purified Tat protein. These cell lines constitutively pro.
duce very low levels of virus in the absence of Tat, as measured
by p24 antigen levels. Virus production can be increased
>30,000-fold by adding exogenous Tat. Tat addition increases
mRNA levels early in the viral life cycle, and Tat is required for
Rev function to become evident. There is no evidence for a
translational effect of Tat. Nuclear run-on experiments show
that the increase in mRNA levels is due to an increased
efficiency of elongation of nascent transcripts. These results
suggest that Tat may be a gene-specific elongation factor.
The Tat protein from human immunodeficiency virus type 1
(HIV-1) is a potent viral transactivator that is essential for
viral replication. The precise mechanism of transactivation
has been unclear. Several studies have shown that Tat
increases the rate of transcription from the HIV long terminal
repeat (LTR) (1-7), and some have suggested that Tat also
increases translational efficiency (2-4, 8-10). Whether the
transcriptional effect results from an increased rate of initi-
ation or elongation has not yet been clearly determined. An
elongation mechanism is supported by steady-state RNA
analyses (11, 12), nuclear run-on experiments (7), and recent
experiments using an in vitro transactivation system (13) and
is consistent with the observation that Tat acts on nascent
RNA transcripts (14).
Transactivation by Tat requires a region near the start of
transcription in the viral LTR called the transacting-
responsive (TAR) element (15). TAR RNA forms a stable
stem-loop structure (4); Tat binds to a 3-nucleotide bulge in
TAR (16-18), whereas cellular factors bind to a 6-nucleotide
loop (19-21). Tat RNA-binding is important for transactiva-
tion both in vivo (16, 18) and in vitro (13), whereas the role of
cellular factors remains to be determined.
Most studies to date have examined the mechanism of Tat
transactivation by using transient assays and heterologous
reporter systems. Here we describe the mechanism of action
of Tat using intact HIV-1. We have taken advantage of the
fact that purified Tat protein can be taken up by cells, enter
the nucleus, and transactivate the HIV promoter (22, 23). By
complementing Tat-defective viruses with purified protein,
we have been able to precisely follow the action ofTat during
the viral life cycle. We show that HIV-1 gene expression is
temporally regulated and that Tat transactivation precedes
Rev function. Analysis ofRNA and protein expression shows
that most, or all, of the Tat effect is transcriptional and that
the increase in viral mRNAs results primarily from increased
efficiency of elongation. Our results present a simple view of
Tat function in HIV-1 and suggest that control of transcrip-
tional elongation may be an important mechanism for regu-
lating cellular gene expression.
MATERIALS AND METHODS
Viruses and Cells. Wild-type HIV-1 particles were gener-
ated by transfection ofthe proviral plasmid R7/3, a derivative
of sp65 HXBgpt (8). R7/Neo, R7/pNeo (-), and R7/pNeo
(+) viruses are described in Fig. 1. CEM and H938 (25) cells
were grown in RPMI 1640 medium/10% fetal bovine serum,
and HeLa cells were grown in Dulbecco's modified Eagle's
medium/10% fetal bovine serum.
Transfections and Infections. CEM cells were electropo-
rated with 20 ,g of supercoiled plasmid DNA per 107 cells,
and HeLa cells were electroporated by using linearized
plasmid DNAs. Tat-mutant viruses were generated by treat-
ing 107 transfected cells with purified Tat protein (22, 26) at
10 gg/ml. After 24 hr, cells were pelleted, and the superna-
tant was used to infect fresh CEM cells. Stable CEM cell lines
were selected in G418 at 1 mg/ml and cloned by limiting
dilution. Transfected HeLa cells were selected in G418 at 500
gg/ml.
Tat Complementation Assays. CEM or H938 cells (2.5 X
107) were treated with purified Tat protein, residues 1-72 (22,
27) at 10 gg/ml in 1 ml of medium containing protamine
sulfate at 100 gg/ml. Protamine significantly enhances up-
take and transactivation by exogenous Tat (D. A. Mann and
A.D.F., unpublished work). Cells were incubated at 370C for
15 min and then diluted to 106 cells per ml. HeLa cells were
scrape-loaded with 10 ,ug of Tat in 2 ml of medium containing
100 ,uM chloroquine (27). Cells were lysed in 50 mM
Tris HCI, pH 8.0/150 mM NaCI/phenylmethylsulfonyl fluo-
ride at 100 Ag/ml/1% Nonidet P-40 and centrifuged to pellet
nuclei. Protein concentrations were measured by the bicin-
chonic acid method (Pierce). HIV-1 viral core antigen (p24)
and neomycin phosphotransferase were quantitated by
ELISA (DuPont/NEN and 5 Prime -* 3 Prime, Inc., respec-
tively), and chloramphenicol acetyltransferase (CAT) assays
were done as described (27).
RNA Analysis. Total RNA was isolated by the hot acidic
phenol method (28) for RNase protection experiments and by
guanidinium isothiocyanate/CsCI gradient centrifugation
(29) for Northern (RNA) blots. 32P-labeled HIV-1-specific
RNA probes were prepared by in vitro transcription of an
EcoRV-linearized plasmid containing the EcoRV (-120) to
HindIu! (+80) fragment ofthe viral LTR and were purified on
Sephadex G-50 spin columns. RNase protection experiments
were done as described (30). Twenty micrograms of cellular
RNA was hybridized overnight with 5 x 105 cpm of the RNA
probe at 38°C in 40 ,ul of 80% (vol/vol) formamide/40 mM
Pipes, pH 6.7/200 mM NaCl/1 mM EDTA. Single-stranded
Abbreviations: LTR, long terminal repeat; CAT, chloramphenicol
acetyltransferase; TAR, transacting-responsive element.
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FIG. 1. Map of Tat-defective neo' viruses. (A) The neo gene was
cloned into the nefregion (between nucleotides +8375 and +8630) of
the HIV-1 genome under control ofthe polyoma enhancer/thymidine
kinase (PTK) promoter cassette (1.1 kb from pMCIneo; ref. 24) in
both the sense [R7/pNeo (-)] and antisense [R7/pNeo (+)] orien-
tations. A promoterless neo gene was cloned at the same nefposition,
and its expression was driven by the 5' HIV LTR (R7/Neo). (B) Tat
mutations were introduced by deleting the second nucleotide (U;
open triangle) in the tat initiation codon (4) and by inserting a
synthetic Mlu I linker into the Bsu36I site of R7/3 at amino acid 43.
RNA was digested with RNase A at 10 ,ug/ml and RNase T1
at 45 units per ml in 400 /Ld of 10 mM Tris'HCI, pH 7.5/300
mM NaCl/5 mM EDTA for 1 hr at room temperature.
Protected fragments were electrophoresed on 6% polyacryl-
amide-7 M urea sequencing gels and quantitated with a
Betascope 603 (Betagen, Waltham, MA). For Northern blots,
20 pug oftotal cellularRNA was fractionated on 1.2% agarose-
formaldehyde gels and transferred and hybridized as de-
scribed (30).
Nuclear Run-on Transcription Assays. Nuclei were pre-
pared (31), and nuclear run-on assays were as described (32),
with the addition of a hot acidic phenol-extraction step after
labeling. For hybridization probes, DNA fragments from the
HIV-1 genome were cloned, in both orientations, into
ml3mpl9. Clones containing a -18 to +79 fragment were
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FIG. 2. Northern blot analysis and Tat complementation ofCEM
Tat- cell lines. (A) Northern blot of CEM cells infected with the
wild-type Tat neo+ virus (2-hr exposure) and Tat- CEM cell lines
(12-hr exposure). The 10.0-kb, 5.1-kb, and 2.8-kb RNAs correspond
to the full-length genomic and singly and doubly spliced mRNAs,
respectively. Because the blots were hybridized with an LTR probe,
the neo transcript terminating in the 3' LTR in the wild-type virus and
in the sense-orientation Tat- viruses is also seen. Independent clones
express slightly variable basal levels of viral mRNAs. (B) Dose-
response of Tat protein complementation. Cells (106) were treated
with the indicated doses ofTat, and p24 antigen levels were measured
after 24 hr.
provided by M. Laspia (Cold Spring Harbor Laboratory,
NY). Human y-actin probes were constructed by cloning the
BamHI-HindIII fragment of pHFl (33) into ml3mpl8 and
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FIG. 3. Time course of Tat comple-
D mentation in CEM Tat- cells. (A) Map
showing the location and sizes of frag-
ments generated by RNase protection
using a probe from -120 to +80 of the
LTR. (B) Cells were treated with Tat
protein, and RNA was prepared, and an-
alyzed by RNase protection at the times
indicated. The protected fragment from
the 5' LTR extends from the cap site (+1)
to +80; the 3' LTR fragment extends
from +8996 to the poly(A) signal at
+9195 (equivalent to -120 to +80 in the
5' LTR). (C) Northern blot analysis of
RNA from the same cells. (D) RNA from
the RNase protection in B was quanti-
tated and compared with p24 antigen
levels.
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ml3mpl9. Five micrograms of single-stranded m13 DNAs
was UV-crosslinked to nitrocellulose filters, and hybridiza-
tion, washing, and RNase treatment were as described (32).
RESULTS
Tat-Defective Virus Cell Lines. To obtain cell lines contain-
ing faithfully integrated Tat-mutant HIV-1 proviruses, we
constructed proviruses that contained a selectable marker
(neo) in place of a portion of the nefgene, which is dispensible
for viral replication (Fig. 1A). Mutant tat genes were intro-
duced into the proviruses (Fig. 1B); these are completely
inactive for transactivation. Plasmids containing the mutant
proviral genomes were transfected into CEM cells, and the
cells were treated with Tat protein to complement the tat
mutations and produce infectious viral particles (see below).
The supernatant containing Tat- viruses was used to infect
fresh CEM cells, and stable integrants were cloned.
Northern (RNA) blot analysis of several cloned Tat- virus
cell lines shows that each has a similar pattern of RNA
expression (Fig. 2A). Interestingly, the low level of unspliced
[10 kilobase (kb)] and singly spliced (5.1 kb) viral mRNAs is
similar to that seen with Rev mutants (8) and suggests that
little or no Rev is produced in the absence of Tat.
To test how efficiently exogenously added Tat protein
complements Tat-defective viruses, Tat- cells were treated
with increasing amounts of Tat, and virus production was
measured. Levels of p24 increased linearly up to a Tat
concentration of 10 jig/ml, resulting in transactivation of
>30,000-fold (Fig. 2B). The ability of Tat 1-72 to fully
complement the Tat deficiency shows that the first exon of
Tat is sufficient to support viral replication. Similarly, be-
cause both mutations prevent expression of Tev (a tat-env-
rev fusion protein; refs. 34 and 35), we conclude that Tev is
not essential for viral replication.
Time Course of Tat Transactivation in Tat- Virus CEM
Cells. To examine the time course ofTat action and assess the
possible effects ofTat on transcription and/or translation, we
treated a CEM Tat- cell line with Tat protein and monitored
expression of viral RNAs by RNase protection and Northern
blotting and measured protein expression by determining the
intracellular levels of p24. An RNA probe complementary to
-120 to +80 of the LTR, which hybridizes to both the 5' and
3' LTRs and yields protected fragments of 80 and 200
nucleotides, respectively (Fig. 3A) was used for the RNase
protection experiments. After 15 min of Tat treatment, a
significant increase in full-length viral mRNAs was apparent
by RNase protection (Fig. 3B); the maximum was reached by
6 hr. Both the 5' and 3' LTR-derived RNAs increased
equally, suggesting that all transcripts initiated after Tat
addition were completely elongated. In the absence of Tat
(time 0), short transcripts approximately the size of the TAR
stem-loop (57 nucleotides) were also seen and did not change
significantly during the Tat treatment (Fig. 3B). Actinomycin
D treatment completely blocked transactivation (data not
shown), suggesting that new transcription is required for Tat
function and showing that the increase in RNA does not
result from mRNA stabilization.
The pattern of RNA expression in the CEM Tat- time
course was also followed by Northern analysis to determine
which classes of viral mRNAs were being expressed as Tat
transactivation proceeded (Fig. 3C). As with the RNase
protection analysis, mRNA levels increased soon after Tat
addition (30 min) and showed maximum expression by 6 hr.
The distribution of viral mRNAs shifted from predominantly
spliced mRNAs to unspliced and singly spliced mRNAs,
indicating that Tat transactivation increased Rev expression.
This result strongly supports the idea that HIV-1 gene
expression is temporally regulated (36), and that Tat function
precedes Rev function.
Levels of intracellular p24 were measured to determine the
time course of protein expression. In contrast to the rapid
RNA increase, p24 expression did not significantly increase
until 2 hr after Tat addition (Fig. 3D). Such a lag was expected
because p24 expression first requires transcription and trans-
lation of Rev before its own mRNA can be translated. The
level of p24 plateaued 12 hr after Tat addition and increased
19,000-fold; total RNA levels increased 38-fold (Fig. 3D).
The difference in transactivation between p24 protein and
RNA levels is almost certainly due to a low level of Rev
expression in the Tat- viruses. Without Rev, virtually all of
the unspliced genomic mRNA, which encodes p24, is located
in the nucleus and cannot be translated (37).
Time Course of Tat Transactivation in Tat- Virus HeLa
Cells. To directly determine whether the difference in RNA
and p24 induction seen in the CEM Tat- virus cells reflects
low Rev expression, we measured the time course of trans-
activation in Tat- virus HeLa cells. In these cells the neo
gene is under control of the HIV LTR, but, unlike p24 (gag),
neo is located on a spliced mRNA, and so its expression is
Rev-independent. This situation allowed us to monitor two
reporter proteins simultaneously-one Rev-dependent (p24)
and one Rev-independent (neo)-in addition to RNA expres-
sion. The pattern of viral RNA expression in the HeLa Tat-
cells was virtually identical to that seen in the CEM Tat-
cells: RNA levels increased rapidly after Tat addition and
reached a maximum after 6 hr, and identical short transcripts
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FIG. 4. Time course of Tat complementation in HeLa Tat- cells.
(A) HeLa cells (107) were scrape-loaded with Tat protein (33), and
RNA was analyzed by RNase protection as in Fig. 3. ', min; h, hr.
(B) Quantitation of RNA, p24 antigen, and neomycin phosphotrans-
ferase.
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CAT
RNA FIG. 5. Time course of Tat comple-
mentation in H9 CAT reporter cells. (A)
Map of the murine sarcoma virus (MSV)
retroviral vector used to establish the
H938 cell line (25). (B) Cells were treated
with Tat protein, and RNA was analyzed
by RNase protection. (C) CAT assay of
20 the time course. (D) Quantitation ofRNA
and CAT activity.
were present that did not change in response to Tat (Fig. 4A).
The pattern of p24 expression was also similar; a much larger
increase of p24 occurred as compared with RNA (2500-fold
vs. 36-fold; Fig. 4B). In striking contrast, neomycin phos-
photransferase II increased by 30 min after Tat addition and
was directly proportional to the increase in RNA (Fig. 4B).
This result strongly suggests that the entire Tat effect occurs
at the transcriptional level and that there is no translational
component.
Time Course of Tat Transactivation in an H9 CAT Reporter
Cell Line. To compare the kinetics of Tat transactivation in
the Tat- viruses with a different reporter, we measured RNA
and protein expression in an H9 lymphoid cell line containing
HIV LTR CAT (25). This cell line was established by
infection with a murine sarcoma virus retroviral vector
containing CAT under control of the HIV-1 LTR and neo
under control of a simian virus 40 promoter (ref. 25; Fig. 5A).
RNase protection using the HIV LTR probe gives an 80-
nucleotide fragment corresponding to expression from the
HIV LTR and a 200-nucleotide fragment corresponding to
expression from either the upstream murine sarcoma virus or
simian virus 40 promoters (Fig. 5A). RNA expressed from the
HIV LTR increased after Tat addition, showing kinetics
similar to those seen in the CEM and HeLa Tat- virus lines,
A
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whereas transcription from the upstream murine sarcoma
virus or simian virus 40 promoters actually decreased (Fig.
5B). Thus, Tat transactivates only the HIV promoter, even
though upstream promoters contribute to basal-level expres-
sion of CAT mRNA.
CAT protein expression increased 47-fold after Tat addi-
tion (Fig. 5 C and D), while the RNA level increased only
6-fold (Fig. SD). At first glance, this result might suggest a
posttranscriptional effect of Tat; however, it is more likely
that this reflects the relative translation efficiencies of
mRNAs derived from the upstream promoters and from the
HIV promoter rather than a translational effect of Tat. Such
effects on basal-level expression or those resulting fromDNA
context, also seen by others (38), may account for reported
differences between RNA and protein transactivation that
have led to suggestions of a posttranscriptional role for Tat.
The Major Effect of Tat Is on Transcriptional Elongation.
Previous studies suggested that Tat may work, at least in
part, by increasing the efficiency of transcriptional elongation
(7, 11). To examine this hypothesis within the virus, we
performed nuclear run-on experiments using probes comple-
mentary to several regions of the full-length genomic tran-
script (Fig. 6A). As has been observed (7), there is a strong
polarity to HIV transcription in the absence of Tat, and
FIG. 6. Transcriptional nuclear run-on of
CEM TatF cells. (A) Map showing the location
of the five DNA probes used to determine the
polarity of transcription across the HIV-1 ge-
nome. The probes correspond to sequences
is from wild-type HIV-1: probe 1, -18 to +79;
probe 2, +80 to +633; probe 3, +634 to +1260;
ense probe 4, +4987 to +5610; probe 5, +8624 to
+9098. (B) Nuclear run-on assay of CEM Tat-
virus cells, Tat- cells treated with Tat for 1 hr
and 2 hr, and wild-type (Tat+) virus-infected
cells. After the run-on reaction, the labeled
RNAs were hybridized to anti-sense probes 1-5,
with sense probes 1-S serving as negative con-
trols. A -y-actin probe was included as an inter-
nal control to normalize for the efficiency of
each run-on reaction.
Tat+viru
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B
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polymerase density markedly decreases within a few hundred
nucleotides from the 5' end and virtually no transcription is
detectable proceeding to the 3' end (Fig. 6B). Significantly,
even without Tat, a high level of promoter-proximal tran-
scripts is seen, suggesting a high initiation rate. By 1 hr after
Tat addition, distal transcription increases markedly, virtu-
ally eliminating the polarity (Fig. 6B). Tat does not seem to
affect initiation because the level of the most-5' transcript is
unchanged. Because the 5' and 3' ends of the mRNAs
increased equally, as observed by RNase protection (Fig.
3B), we conclude that all transcripts initiated in the presence
of Tat progress to the 3' end and become polyadenylated.
DISCUSSION
By complementing Tat-defective viruses with the Tat pro-
tein, we have shown that (i) Tat acts early in the HIV-1 life
cycle and precedes Rev function and (ii) transactivation
results primarily from increased transcriptional elongation.
These observations indicate that regulation of HIV-1 gene
expression by Tat may be relatively simple but exceedingly
powerful. In the absence of Tat, the HIV-1 promoter initiates
transcription at a high rate, but nascent transcripts are
inefficiently elongated and Rev expression is low. When Tat
is added, elongation proceeds efficiently, and large amounts
of full-length genomic transcripts are produced. This results
in increased Rev expression, which causes accumulation of
unspliced mRNAs and expression of viral structural proteins.
Thus, Tat regulates two stages of HIV-1 gene expression: Tat
acts directly to increase the rate of synthesis of full-length
transcripts and acts indirectly by controlling Rev expression.
Tat transactivation within HIV-1 is due primarily to in-
creased efficiency of transcriptional elongation. In the ab-
sence of Tat, two classes of RNAs are seen in the Tat-
viruses; a low level of full-length genomic RNAs and rela-
tively abundant short RNAs (Fig. 3B). The full-length
mRNAs are very stable (they decrease only slightly after 2 hr
of actinomycin D treatment; data not shown), suggesting that
even this low level represents RNAs accumulated from many
prior rounds of initiation. The abundant short RNAs, which
appear to be degradation products from incompletely elon-
gated RNAs (39) rather than products of a specific termina-
tion site (11), suggest that the rate of initiation is high. When
Tat is added, the level of genomic mRNA increases, and
virtually all initiated transcripts are efficiently elongated. In
a wild-type Tat' virus, elongation proceeds efficiently, con-
tinuously generating full-length mRNAs, and no short tran-
scripts accumulate (Fig. 3B). Nuclear run-on experiments
support increased elongation; the striking polarity to tran-
scription in the absence ofTat is completely overcome by Tat
addition (Fig. 6). Without Tat, the fall-off in transcription is
gradual, rather than the result of a specific termination site.
Tat does not appear to increase initiation because transcrip-
tion near the 5' end of the genome is unaffected by Tat. These
results support certain aspects of previous studies, showing
effects of Tat on transcriptional elongation (7, 11, 13, 38), and
suggest that this mechanism may account for the entire effect
of Tat within the virus.
Control at the level of transcriptional elongation provides
a rapid switch to turn on gene expression. By assembling
transcription complexes that lack a factor required for effi-
cient elongation, a promoter can efficiently initiate transcrip-
tion and be primed for high-level expression as soon as the
missing component is supplied. In essence, Tat may be a
gene-specific elongation factor, targeted to the HIV-1 pro-
moter by binding to TAR RNA. Once bound to the nascent
transcript, Tat might then be positioned to interact directly
with the elongation complex to prevent premature termina-
tion. Viruses such as HIV-1 may have evolved such a
mechanism to allow for rapid expression after a period of
latency. Perhaps cellular genes that show rapid fluctuations
in expression during the cell cycle, such as c-myc, may be
effectively regulated through transcriptional elongation (40),
the timing of which is determined by expression of gene-
specific elongation factors.
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